This is a contrast between Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) and Molecular Templates Inc. (NASDAQ:MTEM) based on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Diffusion Pharmaceuticals Inc. N/A 0.00 19.60M -0.45 0.00
Molecular Templates Inc. 9.42M 18.17 30.57M -1.13 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Diffusion Pharmaceuticals Inc. and Molecular Templates Inc.


Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Diffusion Pharmaceuticals Inc. 0.00% -79.1% -69.4%
Molecular Templates Inc. -324.52% -38.6% -29.9%

Risk and Volatility

Diffusion Pharmaceuticals Inc. is 231.00% more volatile than Standard and Poor’s 500 because the company has a beta of -1.31. Molecular Templates Inc.’s 3.15 beta is the reason why it is 215.00% more volatile than Standard and Poor’s 500.


Diffusion Pharmaceuticals Inc.’s Current Ratio is 12.2 while its Quick Ratio is 12.2. On the competitive side is, Molecular Templates Inc. which has a 2.8 Current Ratio and a 2.8 Quick Ratio. Diffusion Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Molecular Templates Inc.

Institutional and Insider Ownership

Roughly 10.7% of Diffusion Pharmaceuticals Inc. shares are held by institutional investors while 70.8% of Molecular Templates Inc. are owned by institutional investors. Insiders held roughly 3.37% of Diffusion Pharmaceuticals Inc.’s shares. Comparatively, Molecular Templates Inc. has 0.7% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Diffusion Pharmaceuticals Inc. -28.54% -48.11% -51.34% -64.27% -85.5% -83.04%
Molecular Templates Inc. -15.73% -15.07% -3.98% -27.3% -38.53% -56.69%

For the past year Molecular Templates Inc. has weaker performance than Diffusion Pharmaceuticals Inc.


Molecular Templates Inc. beats Diffusion Pharmaceuticals Inc. on 5 of the 9 factors.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM. Diffusion Pharmaceuticals Inc. is headquartered in Charlottesville, Virginia.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin’s lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *